Histological and molecular subtyping of medulloblastoma using immunohistochemical markers by Magesh, P
1 
 
HISTOLOGICAL AND MOLECULAR SUBTYPING OF 
MEDULLOBLASTOMA USING IMMUNOHISTOCHEMICAL MARKERS 
 
 
A DISSERTATION SUBMITTED IN PART  
FULFILLMENT OF THE REGULATION FOR THE  
AWARD OF THE DEGREE OF M.D. PATHOLOGY  
BRANCH III 
 
 
 
 
 
THE TAMIL NADU DR. M.G.R. UNIVERSITY 
CHENNAI, TAMIL NADU 
APRIL-2016 
 
 
2 
 
 
3 
 
 
4 
 
 
CERTIFICATE 
This is to certify that this dissertation titled “HISTOLOGICAL AND 
MOLECULAR SUBTYPING OF MEDULLOBLASTOMA USING 
IMMUNOHISTOCHEMICAL MARKERS ”, is the bonafide work 
done by me,  Dr. Magesh, under  the guidance of  Dr.Geeta Chacko,  in 
part fulfillment of the rules and regulations for the M.D.Branch III 
(Pathology) Degree Examination of Tamil Nadu Dr. M.G.R. Medical 
University, to be held in April 2016.  
 
Dr. Magesh P 
Postgraduate  Registrar, 
Department of General Pathology, 
Christian Medical College, 
Vellore, Tamil Nadu 
India. 
 
 
5 
 
 
6 
 
 
7 
 
 
 
 
 
8 
 
 
 
 
 
ACKNOWLEDGEMENT 
I express my warm thanks to Dr.Geeta Chacko(General pathology) and Dr. Bimal patel 
(General pathology)  for their guidance and persistent help for the completion of this 
dissertation. 
 
 
 
 
 
 
 
 
9 
 
ABBREVIATIONS 
AXIN                Axis Inhibition of Wnt Pathway 
APC                  Adenomatous polyposis coli 
BCL2                B cell lymphoma 2 
BCLxl               B cell lymphoma xL 
CNS                  Central nervous system 
CSF -                 Cerebrospinal fluid 
CTNNB1           Catenin (Cadherin-Associated Protein), Beta 1  
 CDK6-              Cyclin-dependent protein kinase  
DKK1 -              Dickkopf  WNT signaling pathway inhibitor 1 
 DSH                  Disheveled 
ERBB2               Avian erythroblastosis oncogene B 
EGL                    External  Granular Layer 
FLI A                  Friend leukemia virus integration A 
FGF                     Fibroblast growth factor 
GAB-1                Growth factor receptor-bound protein 2 associated-binding protein 1 
GSK-3Beta         Glycogen synthase kinase-3Beta 
GNP                    Granule neuronal precursors 
GRM8                 Glutamate receptor metabotropic 8 
HDAC 5              Histone Deacetylase 5 
JAG                     Jagged 
KDM6A              Lysine (K)-Specific Demethylase 6A) 
KCNA                 Potassium channel gene 
LEF                     Lymphoid enhancer factor 
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MAX                  myc-associated factor X 
MBEN              Medulloblastoma with extensive nodularity 
MYC L             Avian MC29 myelocytomatosis  
MYCN              Avian MC29 myelocytomatosis 
MIB-1                Mind Bomb 
MRI                   Magnetic resonance imaging. 
NPR-3               Natriuretic Peptide Receptor 3 
OTX2                Orthodonticle 
PNET                Primitive Neuroectodermal tumour 
PTCH                Patched 1 
SHH-                Sonic Hedgehog 
SFRP1              Secreted frizzled-related protein 1 (SFRP1) 
SMO                 Smoothened 
SUFU                Supressor of fused homolog 
TCF                   T-cell transcription factors 
TSG APC          Tumour suppressor gene Adenomatous Polyposis coli. 
VEGF                Vascular Endothelial Growth Factor 
WNT                 Drosphila melanogaster wingless gene. 
WIF1                 WNT-inhibitory factor 1. 
YAP-1               Yes associated protein. 
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OBJECTIVES:   
 To study the demographic,  histological features and expression profile of the 
immunohistochemical markers β-catenin, GAB-1 and NPR-3 in adult and paediatric 
medulloblastomas and to correlate the expression of these three markers with the 
histological subtypes of medulloblastoma. 
METHODS:  
 One hundred and thirteen cases of  medulloblastoma were included in this study. A 
detailed review of the H&E stained slides and previous immunohistochemical studies 
was done. Immunohistochemistry for β-catenin, GAB-1 and NPR-3 were performed 
on all 113 cases. Correlation between patient demographic profile, morphological 
subtypes and immunohistochemical markers was done. 
RESULTS:  
Medulloblastomas are primarily tumors of childhood and 77% of the study 
population was children. The mean age at diagnosis of medulloblastomas was 13 
years.  In children there was a clear male preponderance, whilst in adults there was a 
near equal gender distribution. Medulloblastomas occurred predominantly in the 
midline with only a quarter arising laterally in the cerebellar hemisphere. The 
predominant histological subtype corresponded to the Classic variant. Desmoplastic 
medulloblastomas formed the next major histological variant, followed by the Large 
Cell variant. Anaplastic and Medulloblastoma with extensive nodularity (MBEN) 
subtypes formed <5% of medulloblastomas. Medulloblastomas in the cerebellar 
hemispheres were predominantly of the Desmoplastic variant. WNT signaling 
activation was seen in 44.2% of medulloblastomas, and in the majority of cases with 
Classic histology 65.7%. Shh signaling activation was seen in 23% of 
medulloblastomas, predominantly in the desmoplastic variant. The non WNT/Shh 
sub-group constituted 34.5% of medulloblastomas. 
Keywords : medulloblastoma, β-catenin, desmoplastic, cerebellar hemisphere. 
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INTRODUCTION 
Medulloblastoma is an aggressive embryonal tumour of the central nervous system(CNS) 
primarily of the paediatric age group with an inherent tendency to metastasize via 
cerebrospinal fluid (CSF) pathways.(1) It accounts for nearly 20%  of all CNS 
tumours.(2)  According to the WHO 2007 classification, these tumours are assigned a 
grade of  IV owing  to their aggressive behavior, high proliferative potential and poor 
outcome.(3)  Recent literature suggests that along with histomorphological classification, 
molecular  subclassification of  medulloblastomas  helps  in clinical risk  stratification  
and predicting  clinical outcome.(4) 
Histological subtypes: 
According to the  WHO 2007 classification, there are five histological subtypes of 
medulloblastoma(3): 
1. Classic variant  
2. Desmoplastic/nodular variant 
3. Medulloblastoma with extensive nodularity  
4. Anaplastic variant  
5. Large cell variant 
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Classic variant: 
Classic variant has closely packed round to oval shaped cells with hyperchromatic nuclei 
surrounded by scant cytoplasm. Neuroblastic rosettes (Homer Wright rosettes) are 
observed in 40% of cases. 
Desmoplastic /nodular variant: 
Desmoplastic variant is characterized by nodular reticulin free zones (pale islands) 
surrounded by densely packed highly proliferative cells. 
Medulloblastoma with extensive nodularity: 
This was previously described as cerebellar neuroblastoma and has expanded lobular 
architecture due to the fact that reticulin free zones become unusually enlarged and rich 
in neuropil like tissue. Internodular areas are markedly reduced in some areas. 
Anaplastic variant: 
Increased nuclear pleomorphism, nuclear moulding, cell-cell wrapping and high mitotic 
activity characterise this variant of medulloblastoma. Apoptosis is prominent in this 
variant.  Presence of these features in focal areas is not sufficient. 
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Large cell medulloblastoma: 
2-4% of medulloblastomas come under the large cell variant and comprise 
monomorphous population of cells with large, round, vesicular nuclei, prominent nucleoli 
and variable amount of cytoplasm. Mitotic and apoptotic figures are abundant.(5) 
Molecular sub grouping of medulloblastoma: 
Based on genetic analysis using mRNA based expression analysis and DNA based copy-
number analysis as well as whole genome sequencing studies, gene expression signatures  
for medulloblastoma have been identified that can predict  patients survival with more 
accuracy than clinical risk stratification.(6)  
There are  four molecular subtypes based on recent literature.(7)  
                     1. WNT subtype. 
                     2. SHH subtype. 
                     3. Group 3. 
                     4. Group 4. 
WNT subtype: 
WNT- Wingless signaling pathways. These are proteins which activate the 
transmembrane frizzled receptors which locks the β-catenin from binding with APC, 
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Axin 1 and 2, caesine kinase1, GSK-3B.  As a result β-catenin is not degraded and is 
translocated into nucleus activating the cyclin D and C-myc.(8, 9) 
Recent studies by Min et al(7) have shown that medulloblastomas with activation of the  
WNT signaling pathway  affected the older children,  showed a classic histology with 
nuclear expression of β-catenin, CTNNB1-mutation, monosomy 6 and had a relatively 
good prognosis. 
SHH subtype: 
During normal Sonic hedgehog pathway (SHH) signalling, SHH ligand binds to PTCH 1, 
which releases receptor smoothened (SMO) from inhibition which in turn activates the 
Gli transcription factor and transcription occurs in the nucleus. So in medulloblastoma 
loss of PTCH and mutation in SMO  or Sufu causes accumulation of Gli transcription 
factor. Min et al(7), found medulloblastoma with SHH pathway in infants and young 
adults was associated with the desmoplastic variant, GAB-1 expression, PTCH deletion 
and an intermediate prognosis. 
Group 3 and 4: 
Group 3 medulloblastomas are frequently seen in infants and children with classic 
/anaplastic histology with poor prognosis.(7)  Group 4 patients with intermediate 
prognosis showed a classic or large cell/anaplastic histology. Genetic studies revealed 
dysregulation of histone methylation occurs in group 3 and group 4. Additionally, 
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mutation in KDM6A family showed dysregulation of lysine demethylation in a subgroup 
3 and 4.(8) 
Use of immunohistochemical markers in molecular sub classification: 
Immunohistochemical (IHC) markers have been identified that correspond to certain 
specific genetic signatures seen in medulloblastomas. Use of these IHC markers has been 
reported to help in sub grouping of medulloblastomas. 
Ellison et al, found four immunohistochemical markers to aid in molecular stratification.  
β-catenin was very useful in identifying tumours with WNT signaling pathway defects 
with almost 98% specificity.  Cytoplasmic positivity for GAB-1 was seen in internodular 
areas of desmoplastic variants and therefore useful in identifying tumours with defect in 
SHH pathways. FLI A and YAP-1 negative expression  was reported to be  markers of 
non-WNT/SHH pathway.(10)  The expression of immunomarkers is as shown in the table 
below (Table 1). 
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Table 1: Immunoexpression profile used for molecular subgrouping of medulloblastomas. 
Molecular 
Group 
Immunoreactivity 
GAB1 β – catenin Fillamin A YAP1 
SHH  
Cytoplasmic 
 
Cytoplasmic 
 
Cytoplasmic 
Nuclear   
Cytoplasmic 
WNT  
Negative 
Nuclear             
Cytoplasmic 
 
Cytoplasmic 
Nuclear   
Cytoplasmic 
   Non 
SHH/WNT 
 
Negative 
 
Cytoplasmic 
 
Negative 
 
Negative 
 
Although few studies established clinical correlation with risk stratification based on 
these markers, few other studies found a fair degree of overlap between histological and 
molecular subtypes. (11) 
In more recent years, Northcott et al(12), used another set of four markers, namely 
DKK1, SFRP1, NPR-3 and KCNA 1 for molecular sub-classification of medulloblastoma 
based on the results of genome wide DNA copy number and mRNA expression profiles 
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and found that these markers reliably classified medulloblastomas into four subclasses, 
DKK1 (WNT), SFRP1 (SHH), NPR3 (group C) and KCNA1 (group D).  
However, Min et al(7) who found that while nuclear β-catenin and GAB-1 easily 
identified WNT and SHH groups without any significant overlap use of NPR3 and 
KCNA1 did not appear to be  either specific or sensitive for genetic sub grouping. 
Kool et al(13) performed a meta-analysis of molecular and clinical data on 550 
medulloblastomas from seven independent studies. Their data demonstrated that 
medulloblastoma is not a single disease and that the four major subgroups are 
transcriptionally, genetically, demographically, clinically and prognostically distinct. 
 The meta-analysis also suggested that there are probably subsets within each subgroup. 
The prognostic factors like metastatic stage, histology, and MYC and MYCN 
amplification performed differently in different subgroups. For example, MYC and 
MYCN amplification were found to predict an unfavorable outcome in the entire cohort 
of medulloblastomas. However, MYC amplification was not prognostic in Group 3 and in 
contrast MYCN amplification was prognostic in SHH and Group 4 medulloblastomas. 
This meta-analysis emphasized the need for identifying prognostic markers which would 
serve as prognostic for each subgroup.  
There is a consensus amongst investigators that there are four main subgroups of 
medulloblastomas with demographic, transcriptional, genetic and clinical differences that 
have important clinical implications(Table 2).(14)           
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Table 2: Features of molecular subgroups of medulloblastoma. 
 
There are limited studies from the Indian subcontinent. Das et al(15) in a retrospective 
study performed immunohistochemistry on 30 cases of medulloblastoma using MIB-1, c-
MYC, ERBB2, bcl2 and bclxL. They found that while bcl-2, ERBB2 and MIB-1 were 
potential markers of aggressive behavior, the protein expression patterns did not correlate 
with histological subtypes and that c-MYC expression did not correlate with progression 
free survival.  
Kunder et al (16) have done microRNA profiling based on the 9 miRNAs and 12 protein 
coding genes and found this to have an overall accuracy of 97%. In this study, age at 
Molecular 
subtypes 
Age Gender 
M:F 
Metastasis Histology Genetic/gene expression  
WNT 
Subgroup 
Children 
followed 
by adults 
 
2:2 
Rarely 
metastasize 
Classic, 
rarely  
large cell 
histology 
CTNNB1 mutation, 
Monosomy 
6,WNTsignaling and 
MYC expression 
SHH 
subgroup 
Commonly 
Infants  
2:2 Uncommonly 
metastasize 
Desmoplastic, 
classic, 
LCA and 
MBEN 
PTCH/SUFU/SMO 
mutations, 9qdeletion, 
MYC N amplification 
Group 3 Commonly 
Children   
2:1 Very 
frequently 
metastasize 
Classic and  
large cell 
morphology 
MYC amplification, 
photoreceptor/GABAergic 
pathways 
Group 4  Children 
and infants 
2:1 Frequently 
metastasize 
Classic and  
large cell 
morphology 
CDK6 amplification, 
neuronal, glutamatergic 
pathways, minimal MYC 
family expression 
9 
 
diagnosis, histology, gender and relative survival rates were found to be similar in the 
medulloblastomas reported from the American and European subcontinents. 
The purpose of our study is to carry out a detailed histological and immunohistochemical 
study of adult and paediatric medulloblastomas using immunohistochemical markers 
GAB-1 and β-catenin and determine the correlation of these two markers with the 
histological subtypes.  
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AIMS 
 
1. To study the histological features of adult and paediatric medulloblastoma and classify 
them into the histological subtypes as defined by WHO. 
2. To study the expression profile of the immunohistochemical markers β-catenin, GAB-
1 and NPR-3 in medulloblastomas. 
3. To correlate the expression of the three markers, β-catenin, GAB-1 and NPR-3, with 
the histological subtypes of medulloblastoma. 
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REVIEW OF LITERATURE 
Central nervous system (CNS) tumors  are  the second  most common  group  of  cancers 
in childhood next  to leukemia(17) and  the  most common solid malignancies of 
childhood.  Gliomas constitute about 50% of the childhood brain tumors with 
astrocytomas forming the predominant subtype and are the most common brain tumour in 
adults. Age distribution shows that primitive neuroectodermal tumours and 
ependymomas are common in children less than 10 years. (17)   
Medulloblastomas are the most common paediatric malignant brain tumours constituting 
approximately 20% of childhood brain tumors.(18)(19)  They are  rare in adults, 
contributing to less than 1% of all adult CNS tumours  and are usually located in the 
cerebellar hemsipheres due to migration of undifferentiated cells from the posterior 
medullary velum to cerebellar hemispheres.(20) 
In the  WHO 2000 classification five entities were defined as belonging to the  
undifferentiated neuroepithelial tumor category  namely,  medulloblastoma, 
supratentorial PNET,   medulloepithelioma,  ependymoblastoma  and  atypical teratoid 
/rhabdoid tumour.(21)   In the WHO 2007 classification, medulloblastoma was identified 
as separate category of embryonal tumour with five different histological subtypes. This 
was based on morphological,  immunohistochemical,  molecular,  clinical  and  biological 
profiles.(3) 
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 Medulloblastomas are small round blue cell tumours with a propensity to metastasize via 
cerebrospinal pathways, resulting in leptomeningeal dissemination as an initial diagnosis 
in 25-30%.  They have an aggressive behaviour and contribute to a substantial number of 
deaths as a result of tumour progression.  Medulloblastomas are  therefore considered as 
WHO Grade IV tumours for their  aggressive behaviour, despite chemotherapy, 
radiotherapy and surgery(22) and  because of their high proliferative potential.   
INCIDENCE, AGE AND GENDER DISTRIBUTION 
Medulloblastomas  account for approximately  6%  of all intracranial tumours.(23) 
Children are 4.6 times more prone for primitive neuroectodermal tumours  than 
adults.(23) Among   primitive neuroectodermal tumours, medulloblastoma is the most 
common, comprising about 95% of PNETs and have an incidence of approximately 0.5 
per 100000 in children less than 15 years of age.  However in children less than 2 years 
of age, astrocytomas and ependymomas are more frequent than medulloblastomas.  
  In a recent multi-institutional study from India, paediatric CNS tumors accounted for 
10-21% of all CNS tumors. Medulloblastomas along with other embryonal  tumours 
comprised the second largest group following glioma, with an average prevalence of  
22.4% of paediatric brain tumors.(24)   In a retrospective study from this institution 
covering over 14  years the incidence of  medulloblastoma was found to be 11.3%.(25) 
In children,  medulloblastomas  have  a bimodal age distribution, with peaks between 3-4 
years and 8-9 years.   In adults the incidence of medulloblastomas are high in the age 
13 
 
group 15 to 19 years and decreases with increasing age. (10)  Most centers consider 
patients upto 18 years as pediatric. Age cut-off of less than or equal to 3 years plays a 
significant role in risk stratification.(26)  Childhood medulloblastomas are more common 
in male than females (1.5:1).  In infants, medulloblastomas may occur as part of familial 
cancer syndromes .(11) 
SITE & HISTOGENESIS (12):  
Medulloblastomas occur at two sites. 
1. Lateral cerebellar hemispheres.  
The external granular layer containing stem cells and pluripotent cells of the 
ventricular subependymal matrix are the cells of origin for the desmoplastic 
variant of medulloblastoma.  
2. Cerebellar vermis.  
The subtypes of medulloblastomas that arise from the cerebellar vermis, originate 
from the ventricular matrix and Purkinje neurons. 
The existence of different histological subtypes of medulloblastomas suggests that 
different cells of origin and different signaling pathways are involved in their molecular 
sub grouping.  Those that arise from the granule neuron precursor (GNP) cells have 
aberrant activation of the sonic hedgehog pathway (Shh). The subgroup of 
medulloblastomas with the Wingless signaling (WNT) pathway activating mutation are 
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found to arise from outside the cerebellum,  mainly from the  lower rhombic lip  and 
embryonic dorsal brainstem instead of  the developing cerebellum.(27)  
There is evidence that medulloblastomas can arise from the granule precursor neuronal 
cell in the cochlear nuclei.(28)   
CLINICAL AND RADIOLOGICAL FEATURES 
Most patients with medulloblastoma present with symptoms of increased intracranial 
pressure due to the blockage of the cerebrospinal pathway in the fourth ventricle.  
Headache, vomiting, lethargy and drowsiness are the usual presenting symptoms.  
Vermian compression and infiltration presents as ataxia while brainstem infiltration and 
compression can cause cranial nerve palsies. (29)  
 Medulloblastoma can be diagnosed using standard neuroimaging techniques. On 
magnetic resonance imaging (MRI), the tumour is visible as a heterogeneously hypo-
intense lesion on T1w images, hyperintense on T2w images, and restricted diffusion on 
the DTI images indicating increased cellularity.  They typically enhance well with 
contrast and may have cysts with or without hemorrhage. (30)  
GENETICS: 
Familial cancer syndromes: 
Though nearly 95% of medulloblastomas are sporadic in origin, initial genetic assessment 
was obtained by studying the familial cases of medulloblastoma. Familial syndromes 
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associated with medulloblastomas are Gorlin syndrome(17), Turcot syndrome(31)  and  
Li-Fraumeni syndrome.(32) 
 
Gorlin syndrome (also known as Naevoid basal cell carcinoma syndrome) occurs due to a 
mutation in the tumour suppressor gene patched 1(PTCH1) which codes for a membrane 
bound receptor involved in developmental sonic hedgehog pathway.  Patients with Gorlin 
syndrome are 600 times more prone to develop medulloblastoma.   Almost 10% of the 
sporadic cases display PTCH 1 mutation.(33) 
Turcot syndrome is characterised by colonic polyps, colorectal cancers and neuro-
epithelial tumours. Two types have been described.  Type 1,  known as Hereditary non 
polyposis colorectal cancer syndrome,  occurs as result of DNA mismatch repair and is 
associated with early onset malignant glioma.(34)  Type 2 occurs as a result of germline 
mutation of TSG APC gene and is associated with an increased incidence of central 
nervous system tumours.  Other familial syndromes associated with medulloblastomas 
are Fanconi’s anaemia,  Rubenstein–Taybi syndrome (35) and  Coffin-Siris 
syndrome.(36)(37) 
Oncogene amplification in medulloblastoma: 
The amplification of oncogenes is a well-defined mechanism for disease progression in 
medulloblastoma.  MYC oncogene is responsible for transformation, cell proliferation, 
differentiation and genomic instability.  MYC amplification  is observed in approximately 
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4% of medulloblastomas.(38)  Increased expression of N MYC promotes proliferation of 
the cerebellar granular cells with anaplastic histology.(39)  Over expression of N MYC  is 
associated with metastatic medulloblastoma.(39) 
 MYC L amplification is rarely observed (1-2%) in medulloblastoma.(40) MYC proteins 
are regulated by their formation of hetero-complexes with MYC associated factor 
X(MAX), which promotes transcription of the genes containing E-box binding site.(41)  
MAX is also able to form repressive complexes with MAD family of proteins, which 
govern the transcriptional status of the targets of the MYC protein.  MYC and MYC N 
amplification occurs rarely(42) in adult medulloblastomas and if present, has a poor 
outcome.(20)  
Recurrent chromosomal abnormalities: 
The most commonly observed chromosomal defect in medulloblastomas are the 
abnormalities of chromosome 17.  Loss of chromosome 17p is seen in 30-40% of cases 
and is commonly associated with reciprocal gain of 17q. This is known as 
isochromosome 17q. (40)  (43)  15% of tumours  have  gain  of  17q  without loss of 17p   
whereas  gain of  whole chromosome  17  is observed  in  5-10%  of tumours.  Loss of 
chromosome 17p in isolation is observed in 20% of the cases and is also seen to be 
associated with  a  poorer prognosis.(44)  
OTX2 in medulloblastomas(45): 
OTX 2(orthodonticle) is a transcription factor which is essential for the growth and 
development of the brain.  During the development of the brain OTX2 is expressed in 
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progenitor cells in prenatal period. This transcription factor is found to be expressed in 
areas of the forebrain,   external granular layer and the developing internal granular layer 
of the cerebellum.  In paediatric brain tumours OTX2 transcription factor is expressed at 
high levels.  OTX2  transcription factor has functional interaction with the MYC 
oncogenes which results in high level expression of these both transcriptional factors in 
medulloblastomas.  In medulloblastomas high level expression of OTX2 transcription 
factor results in cell proliferation. Loss of OTX2 expression has also been found 
responsible for  myogenic  differention in medulloblastoma.(46) 
Abnormal activation of embryonal signaling pathways: 
Cell signaling pathways play an important role in the developmental processes. 
Inappropriate activation leads to inappropriate growth and differentiation.  WNT and 
SHH pathway have been implicated in the pathogenesis of medulloblastoma.(47) 
Sonic hedge hog (SHH) pathway: 
SHH pathway is an important regulator of the embryonic development.  It plays a vital 
role in stem cell maintenance, cell differentiation, proliferation and tissue polarity.  In 
1980,  hedgehog gene spiked phenotype was observed in mutant Drosophila larvae.(48)  
There are 3 mammalian homologues of Drosophila hedgehog gene namely Sonic, Indian 
and Desert hedgehog.  SHH pathway has diverse effects in different cellular contents.  
Sonic hedgehog acts as a morphogen  in  cell  fate  differentiation and  mitogen  in 
development  of organs.(49)  SHH   gene plays a crucial role in cerebellar development.  
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In adults it plays a vital role in proliferation of the adult neural stem cells.(50) Other 
functions include tissue repair, renewal and tissue homeostasis. 
During normal SHH pathway signaling, SHH ligand binds to PTCH 1, which releases the 
receptor smoothened (SMO) from inhibition which in turn activates the signaling 
cascade.  This event is possibly mediated by G-proteins,  that activates  the  GLI family 
of transcription factors,  by forming an activated complex, GLI A that transcriptionally 
activates SHH pathway target genes such as cyclin D1 and MYC N.(50)  In absence of 
SHH ligand,  GLI proteins are proteolytically processed to generate the repressive 
complex,  which prevents SHH target genes from being transcribed.(51)  GLI 1 and GLI 
2 are found to be transcriptional activators and GLI 3 is found to be a transcriptional 
repressor.(52)  In the absence of SHH ligand repressor, GLI R is produced. 
Cerebellar development and role of SHH pathway: 
Developmental processes that occur within the cerebellum are related to the origin and 
pathogenesis of medulloblastoma. The oncogenic abnormalities in the signaling pathways 
may result in the formation of different types of medulloblastoma.(44)  
During early stages of cerebellar development,  cells are derived from two distinct 
germinal zones;  one from precursor cells in the roof of the fourth ventricle, which gives 
rise to GABAnergic precursors,   including Purkinje cells;  the other from cells within the 
rhombic lip,  which comprises of GNP cells, which produce the external granular layer 
(EGL).(44)  The EGL persists into the second year up to the post-natal life.   
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The SHH pathway plays a vital role in the  development of GNP cells and also controls 
the expansion,  differentiation and migration of GNPs in the EGL of the cerebellum.(53) 
The importance of the SHH pathway was further studied by inhibition of SHH signaling 
pathways in mouse models of cerebellar development.  This was found to result in a 
marked decrease in the proliferation of the EGL(54) conversely,  recombinant SHH 
drives the proliferation of GNPs.(55)  
 
Activation of the SHH signaling pathway characterizes approximately 25% of 
medulloblastomas.  Mutations in SHH pathway components (PTCH1, SUFU, SMO) have 
also been described for subsets of medulloblastomas(56).  The mechanisms by which the 
SHH pathway can drive medulloblastoma have been elucidated in mouse models of the 
disease.   10-15% of PTCH1 +/- mice go on to develop medulloblastoma(57) and express 
high levels of GLI 1,  consistent with activation of the SHH pathway.   More than half 
show residual populations of GNP cells at the surface of the cerebellum that fail to 
undergo terminal differentiation and migration to the internal granular layer,  suggestive 
that medulloblastoma arises from these residual populations in this model.(57)  
Activation of the SHH pathway is observed in the majority of infant cases (42) and is also 
associated (although not exclusively) with a desmoplastic phenotype.   A similar 
enrichment has been observed in adult cases, where an incidence of 50% has been 
reported. (43)   Multiple studies have identified distinct sets of differentially expressed 
genes that characterize medulloblastoma with an activated SHH signaling pathway (44) 
20 
 
(45) (46).   No difference in survival has been reported between adult and childhood SHH 
medulloblastomas. (43)  
WNT pathway: 
The WNT signaling pathway plays an important role in embryogenesis and cancer and is 
also important in the regulation of normal physiological processes in adults.  It was  
found that it is recognized to be important in developmental biology, and  its relevance to 
cancer became evident when the interaction with the tumour suppressor genes APC and 
β-catenin was identified.(58)  The identification of mutations in the APC gene, in families 
affected with Turcot syndrome linked their syndrome to inappropriate activation of the 
WNT signaling pathway.  After this it was identified that up to 85% of sporadic 
colorectal cancers were associated with truncating mutations in APC.(59)   Gain of 
function mutations in CTNNB1 (the β-catenin gene) which is most commonly observed in 
WNT pathway activated medulloblastomas however,  have rarely been reported in 
colorectal cancers(60). 
In the absence of WNT ligands, cytoplasmic β-catenin is recruited into a destruction 
complex, consisting of APC, Axin and Glycogen synthase kinase-3β (GSK-3β), where its 
N-terminal is phosphorylated by casein kinase-1α and GSK-3β.(60) After 
phosphorylation, β-catenin is targeted for proteosome mediated degradation, ensuring 
that cytoplasmic levels of β-catenin remain low. (60) 
Activation of the canonical WNT signaling pathway is initiated by secreted WNT 
proteins binding to Frizzled receptors in the plasma membrane. This interaction can be 
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inhibited by several proteins,  including the secreted frizzled related proteins (SFRPs),  
Dickkopfs (DKKs) and WNT-inhibitory factor 1 (WIF1).(60)  In further steps, 
Disheveled (DSH) is recruited to the plasma membrane, where it interacts with Frizzled 
to mediate the translocation of Axin to the plasma membrane and inactivation of the 
destruction complex.  This inactivation enables the cytoplasmic stabilization and 
subsequent translocation of β-catenin to the nucleus.   
 In the nucleus,   β-catenin forms a transcriptionally active complex with the lymphoid 
enhancer factor (LEF) and T cell factor (TCF) transcription factors. Target genes of the 
transcriptional complex include the proto-oncogene,   MYC,   proliferative genes such as 
cyclin D1 and cell signaling genes (VEGF, FGF4 and FGF18).  
Cerebellar development and WNT pathway: 
The role for the WNT pathway in cerebellar development is poorly understood, although 
it has been shown that deletion of the WNT-1 gene, blocks cerebellar development by 
preventing the formation of the midbrain-hindbrain junction from which the  cerebellum 
is developed. (61) Recent work in mouse models reported the expression of WNT 
pathway target genes in the lower rhombic lip of the cerebellum at day 11.5 of embryonic 
development,  and the dorsal brainstem at day 15.5 (62)(19) ,  which helped to identify a 
cell of origin for medulloblastomas with an activated WNT signaling  pathway.  
WNT pathway in medulloblastoma: 
The most commonly observed mutations in medulloblastoma with an activated WNT 
signaling pathway are activating mutations that affect the phosphorylation domain of the 
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β–catenin protein,  affecting 8%  of  sporadic medulloblastomas and~95%  of  WNT-
activated medulloblastomas.(63)   Now, in the absence of WNT ligand, the β-catenin 
protein can no longer be phosphorylated by the complex of APC, Axin and GSK-3β.  
Instead, unmodified β–catenin is free to translocate to the nucleus and initiate 
transcription of proliferative WNT pathway target genes.  Mutations in other WNT 
pathway components have also been identified.  Individuals affected by Turcot  
syndrome harbor mutations in APC (64) , one of the proteins responsible for targeting β-
catenin for degradation and rare mutations of AXIN have also been reported.(50) The  
majority of the    WNT pathway activated  tumours  are of classic histology(65),  occurs 
in non infants and have dual peak of  incidence at 10 and 20 years. They have also been 
associated with a favourable prognosis.(66)  WNT activated tumours have distinct 
molecular  and genomic defects that enable classification of these tumours. 
 
NOTCH signaling pathways in medulloblastomas:(67) 
Medulloblastomas can arise from various deregulated pathways including NOTCH 
signaling pathway.  NOTCH pathway plays a vital role in the normal physiological 
cerebellar development during embryogenesis.  It plays an important role in cell 
differentiation, proliferation and apoptosis.  Activation of NOTCH signaling pathway 
requires the interaction ligands (JAG1, JAG2, DLL1, DLL3 and DLL4) and receptors 
(NOTCH 1-4).   
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As ligand binding proceeds, it triggers the proteolytic cleavage of NOTCH receptors.   
Once released into the cytoplasm, the NOTCH intracellular domain translocates into the 
nucleus and activates a series of transcriptional regulatory pathways.  The aberrancies 
were noted in four ligands - JAG1,   JAG2,   DLL1, and DLL4.   It was found that there is 
over expression of JAG1, DLL1 and down regulation of JAG2 and DLL4 in 
medulloblastomas. (67) 
Subpopulation  of  Group 3  cases expressing high JAG2 levels and up-regulation of 
NOTCH  ligand  DLL1 in  Group 4 cases  and  a down-regulation  of  DLL3  in Groups 3  
and  4  tumors has been observed .  It was found that association between the MYC and 
JAG2 ligands plays a crucial role in group 3 cases.  High levels of expression of JAG2 
correlate with large cell/anaplastic morphology and high rates of metastasis.(67) 
PATHOLOGY: 
Medulloblastoma were originally described as small blue round cell tumours on light 
microscopy.(3) 
HISTOLOGY 
 Medulloblastoma is composed of closely packed cells with round-to-oval shaped 
hyperchromatic nuclei surrounded by scanty cytoplasm.(26) Neuroblastic (Homer 
Wright) rosettes are often associated with medulloblastomas.(3)  Marked nuclear 
pleomorphism and atypia leads to anaplasia in medulloblastomas.  Vascular hyperplasia 
and areas of necrosis are quite uncommon, but when present necrosis can show a 
pseudopalisading pattern.  The most common type of differentiation in medulloblastoma 
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is neuronal which on immunostaining shows positivity for synaptophysin.(13) The 
presence of glial differentiation with astrocytic phenotype is rare in medulloblastomas. 
(13) 
According to the 2007 WHO classification, the Histological subtypes include:  
1. Classic variant  
2. Desmoplastic variant 
3. Medulloblastoma with extensive nodularity (MBEN) 
4. Anaplastic variant  
5. Large cell variant 
1. Classic variant: 
The classic variant constitutes about 70-80% of all medulloblastoma cases. (29) 
This variant is hypercellular and composed of cells with medium sized hyperchromatic 
nuclei surrounded by scant cytoplasm.  .Nucleoli are not prominent.Nuclear moulding 
may be seen due to high cell density. Mitotic activity is brisk as apoptosis. This variant is 
more common in children. Most of these tumours are seen in a  midline location.  
Neuroblastic rosettes (Homer Wright rosettes) representing neuronal differentiation are 
found in about 40% of medulloblastoma and  a characteristic feature of this variant.  
Necrosis and vascular endothelial proliferation are not common.(68)  Linear arrays 
(streaming) is occasionally seen. 
2.Desmoplastic/nodular variant: 
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This variant constitutes about 10-15% of all medulloblastoma cases with a higher 
prevalence among infants and adults.(7) It is more frequently seen in the cerebellar 
hemisphere than in the fourth ventricle.(63) Desmoplastic variant is characterized by 
nodular reticulin free zones (pale islands) surrounded by densely packed highly 
proliferative cells.   Internodular areas are more densely packed and pleomorphic as 
compared to the nodular areas that are pale in comparsion due to increased amount of 
cytoplasm.  Nucleoli are not prominent.  Nuclear moulding may be seen due to high cell 
density. Mitotic activity is brisk as apoptosis.  Desmoplasia was previously associated 
with improved prognosis in infants.  Its prognostic value in non-infants is unclear. Extent  
and increased density of nodules  have improved prognosis.(69). 
3. Medulloblastoma with extensive nodularity: 
This  variant  which was previously described as cerebellar neuroblastoma, comprises 
about 1-2% of all medulloblastomas.(70)  It has an expanded lobular architecture because 
of the unusually large reticulin free zones which are rich in neuropil like tissue.  This 
variant has round cells with uniform nuclei and high level of neuronal differentiation and 
low proliferation index.(71)  It is seen nearly exclusively in infants  and is associated with 
a favourable prognosis. (72) 
4. Anaplastic variant: 
Approximately 10-20% of medulloblastomas comes under this variant. Presence of 
increased nuclear pleomorphism, nuclear moulding, cell-cell wrapping and high mitotic 
activity characterise this variant of medulloblastoma.  Apoptosis is prominent in this 
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variant.(73)  Presence of aforementioned features in focal areas is not sufficient for 
diagnosis of anaplastic variant.(3) 
5. Large cell medulloblastoma: 
Approximately 2-4% of medulloblastoma comes under the large cell variant. (73) 
Monomorphous population of cells with large, round, vesicular nuclei, prominent 
nucleoli and variable amount of cytoplasm are noted.  Mitotic and apoptotic figures are 
predominant. Areas of large cell can be seen alongside the more typical histological 
subtype, classic, desmoplastic, nodular and medulloblastoma with myogenic 
differentiation.  This variant is characterised by poor prognosis.  
Medulloblastoma with myogenic or melanotic differentiation:(74) 
Previously described as medullomyoblastoma , these are tumours that show focal skeletal 
muscle differentiation.(74) These could be in the form of rhabdomyoblast or mature 
skeletal muscle. The cells are positive for desmin, myoglobin and myosin, but not smooth 
muscle actin. (75) Genetic changes in medulloblastoma with myogenic differentiation are 
similar to other subtypes of medulloblastomas. 
Medulloblastomas with melanocytic differentiation were  previously known as melanotic 
medulloblastoma.(76)  These are tumours that show melanocytic or retinal pigmented 
epithelial differerentiation. The melanotic cells can occur in different variants of 
medulloblastoma.  The tumours with myogenic or melanotic differentiation are now 
considered as morphological patterns and not as variants of medulloblastoma. (76) 
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 Rarely encounters medulloblastoma with chondroid differentiation or osseous or 
epithelial differentiation.(77) 
The identification of the different histological variants is clinically useful as the tumors 
with desmoplastic histology are associated with better outcomes while large 
cell/anaplastic medulloblastomas have a poorer prognosis. 
 
The evolution of classification from histology to molecular: 
Current management of medulloblastomas focuses on a maximal safe resection followed 
by craniospinal radiotherapy and adjuvant systemic chemotherapy.  When patients are 
stratified into two groups: average risk including those children > 3 years of age who 
have undergone a gross total resection and no evidence of leptomeningeal metastases 
(M0) and high risk being those patients ≤3 years,  residual tumor >1.5cm2 or with 
evidence of leptomeningeal metastases outcomes are clearly distinct.   Average risk 
patients enjoy a 5-year survival of about 85% while the survival drops to 60-65% in the 
high risk group. (78) 
 
With the recognition that signaling pathway abnormalities, specifically SHH and Wnt, 
play a role in the development and progression of medulloblastomas, it also became 
apparent that this disease is more heterogeneous than previously thought.    Abnormalities 
within each signaling pathway seemed to result in distinct phenotypic presentations that 
had varying biological behavior and aggressiveness leading to different clinical 
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outcomes. (79)   Thus the traditional method of stratifying patients purely on a clinical 
and radiological basis is bound to be fallacious since they do not incorporate this new 
molecular information.   If medulloblastomas are sub-grouped on a molecular basis and 
this information integrated with the clinicoradiological information it is likely that the 
risk stratification and prediction of outcomes will improve.   The obvious benefit of 
improved risk stratification for children with medulloblastomas is the reservation of 
highly toxic chemotherapy for the high risk group and the adoption of a more moderate 
approach for the low risk group thus optimizing outcomes versus treatment 
complications. (80) 
 
Evolution of subgrouping in Medulloblastomas: 
It is evident from the differences between the WHO 2000 and 2007 classification of CNS 
tumors that medulloblastomas were recognized to be distinct subgroup of primitive 
neurectodermal tumors.  Their morphological similarities with PNETs with their small 
blue round cell appearance was misleading because it was soon demonstrated by 
Pomeroy et al (81) using gene expression profiling that medulloblastomas were 
genetically distinct from other malignant embroyonal brain tumours.  Amongst 
neuropathologists it was also apparent for many years that the heterogeneous 
morphological appearance of medulloblastomas lends itself to be classified broadly into 
those that are desmoplastic (medulloblastoma with extensive nodularity and nodular 
desmoplastic medulloblastomas) and those that are large cell or anaplastic. (82) 
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The histological segregation into these two groups led to the recognition that their 
outcomes were different with poorer outcomes for the latter group.  Thus the finding that 
mutations in the PTCH1 gene coding for PTCH1, a receptor for SHH, and two 
downstream targets of SHH namely GLI and N-Myc were highly correlated with the 
desmoplastic variant of medulloblastomas implicated SHH dysregulation in the 
pathogenesis of one subset of medulloblastomas.   
 Later, Gibson et al(27)  confirmed that different subtypes of medulloblastoma have 
distinct developmental and cellular origins. The lower rhombic lip and dorsal brain stem 
expressed the WNT subtype signature and consistent with this is the finding that tumors 
with the WNT signature arise in the floor of the fourth ventricle and infiltrate the brain 
stem. In contrast the gene expression of the SHH subtype was seen in the upper rhombic 
lip and cerebellar hemisphere and SHH pathway tumors are frequently seen to arise in the 
cerebellar hemispheres.   
Between 2006 and 2011, researchers in separate laboratories across the world began 
intensive work on further characterizing molecular subgroups in medulloblastomas(20) 
(83)Using different but complementary techniques ranging from gene expression 
profiling, mRNA expression profiles, mRNA transcriptome profiling and high density 
SNP array and miRNA analysis these authors arrived at 5 distinct molecular subtypes, A 
to E.(83)  They seemed to concur on the findings that each subtype had specific gene 
signatures and distinctive genetic abnormalities but more importantly that each subtype 
had specific clinicopathological features.  The subtypes were characterized by Wnt 
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signaling (Group A), SHH signaling (Group B), neuronal differentiation gene expression 
(Groups C and D) or photoreceptor gene expression (Groups D and E). 
  Furthermore it was determined that tumors with a C-MYC copy number gain were in a 
subgroup with a poor prognosis.(84)(46)The work from Northcott et al(12) in 2011 using 
integrated genome-wide DNS copy number and mRNA expression profiles crystallized 
the classification system into the current recommended grouping.   
 
In addition, using microarray data they developed antibodies against the subgroup-
specific signature genes enabling a immunohistochemistry-based classification thus 
obviating the need for fresh frozen tumor tissue for genomic analysis that was expensive 
and not freely available.   Thus IHC for DKK1 indicating the WNT pathway; SFRP1 
indicating the SHH pathway, NPR3 for Group C and KCNA1 for Group D provided a 
simple method for subgrouping medulloblastomas.   
From India, the Tata Memorial Cancer Center provided microRNA data that seem to be 
consistent in classifying tumors into the WNT pathway subgroup and SHH subgroup 
based on over and under expression of certain microRNAs respectively.(16)   
In 2012 a consensus meeting brought together current knowledge on molecular signatures 
of medulloblastomas and recommended 4 subgroups namely: WNT, SHH, Group 3 and 
Group 4.(85)  The first two named the signaling pathways were considered to be 
instrumental in the pathogenesis of these tumors while the last two were merely called 
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Group 3 and 4 because until that time no specific pathways were implicated in their 
pathogenesis.(85)  
Relevant features of molecular subgroups: 
These molecular subgroups can predict the patient’s survival with more accuracy than 
clinical risk stratification. (53) 
WNT pathway medulloblastomas: 
 This subgroup is rare constituting only 10% of all medulloblastomas, yet they have the 
best prognosis with 5-year survivals of more than 90%. They are seen predominantly in 
the age group of 10-12 years and are less common in less than 4 years of age and are very 
rare in infants. .  It is equally distributed in both genders.(13)   Histologically this group is 
characterized by the classic type of medulloblastoma and some have large cell/anaplastic 
morphology. (53)   
The WNT signaling pathway plays a role in regulating embryogenesis of the brain and 
one of the genes in this pathway,  the adenomatous polyposis coli gene APC is mutated in 
Turcot’s syndrome that predisposes patients to colon cancer, glioblastoma and 
medulloblastoma.(86)  More than 90% of WNT pathway medulloblastomas have 
mutations in CTNNB1, a gene coding for β-catenin that interacts with other transcription 
factors to activate the WNT signaling pathway.(7)  Mutant β-catenin protein accumulates 
in the nucleus of tumor cells.  In addition WNT medulloblastomas also show loss of one 
copy of chromosome 6.(7)  Taken together,  IHC positivity for β-catenin and monosomy 
6 is diagnostic for WNT pathway medulloblastomas.(12)  Other mutations found in this 
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pathway include AXIN 1 and AXIN 2.    This subgroup is also associated with 
amplification of MYC genes and infrequent metastasis.(12) 
SHH pathway medulloblastomas: 
This subgroup is more frequent than WNT tumors occurring in approximately 30% of all 
medulloblastomas.(10)  This group is common both in infants and in patients > 16 years 
of age.(14)  Many SHH tumors display desmoplastic histology, in fact the MBEN variety 
is almost exclusively seen in this subgroup alone.  The majority are lateralized to the 
cerebellar hemispheres consistent with their proposed origin from the granule neuron 
precursor cell.(87) 
The SHH gene codes for the protein patched homologue 1 (PTCH1) that is a receptor for 
SHH and other hedgehog homologues.  SHH signalling drives normal cerebellar 
development, however, unrestrained SHH activity can lead to medulloblastoma 
tumorgenesis.(88)   The fact that PTCH1 mutations occur in only 25-30% of SHH-
associated medulloblastomas indicates that this subgroup is quite heterogenous and 
caused by other genetic abnormalities including SMO and SUFU mutations and 
amplifications of SHH, GLI2 and N-MYC have been noted.(89)  Most infants carry the 
PTCH1 or SUFU mutations  while PTCH1 and SMO mutations typically occurs in 
adults.(14) Immunohistochemistry with SFRP1, GLI and GAB-1 helps in diagnosing this 
subgroup.(72)  They are associated with intermediate prognosis.(7) 
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Group 3 Medulloblastomas: 
This subgroup carries the worst prognosis with a 5-year survival around 50%. (13) 
Fortunately they occur in only 1/4
th
 of all patients, boys being more frequently involved, 
and they almost never occur in adults.(87)  The desmoplastic histology is almost never 
seen in this subgroup; instead the LCA variety predominates occurring in about 40% of 
patients.(87)  In keeping with their poor prognosis, they tend to metastasize via the CSF 
spaces at presentation.(90)   It appears that copy number gains of 17q and C-MYC or N-
MYC amplification impart the poor prognosis to patients in this group(87).   Nonetheless, 
while more than 50% of Group 3 tumors do not display any specific genetic 
abnormalities, extensive variations in chromosome structure exist, the significance of 
which are poorly understood as far as tumorigenesis is concerned.(87)  Group 3 is further 
classified into 3 alpha and 3 beta.(90)  OTX2 transcriptional factor is found to be 
associated with this subgroup.  Other abnormalities include gain of chromosome 1q, loss 
of chromosome 5q and loss of chromosome 10q and has a poor prognosis.(22)  .   
Group 4 Medulloblastomas: 
This subgroup is quite common comprising 35% of all medulloblastomas(85). There is a 
marked male predominance and these tumors are seen across all age groups, but less 
common in infants.(87) The prognosis in this group of tumors is between that of the 
WNT group and Group 3.  Classic and Large cell histology are the common subtypes 
seen in Group 4. Chromosome 17 abnormalities are a hallmark of this subtype.(73) One 
of the common aberrations seen is isochromosome 17q.(7)  HDAC 5gene locus  is 
34 
 
located on the chromosome 17q,  which is commonly amplified in this subgroups.(90) 
Other cytogenetic abnormalities include CDK6 and MYC N amplification.(7).  
There are no familial syndromes associated with this tumor subtype, nor copy number 
alterations or genetic mutations frequent. (72)  35-40% of cases have metastatic disease at 
the time of first presentation(87). The overall 5-year survival ranges from >85% to 
50%.(85)  
 
Use of immunohistochemical markers in molecular sub classification: 
The immunohistochemical(IHC) markers  used are  based on previously identified 
genetic signatures using Fluorescent insitu hybridisation,  MicroRNAs,   comparative 
genomic hybridisation and real-time PCR uniqueness.(12)   IHC markers were used for 
molecular subclassification of  medulloblastomas  namely DKK1, SFRP1, NPR-3 and 
KCNA 1  based on the results of genome wide DNA copy number and mRNA expression 
profiles and it was found that these markers reliably classified medulloblastomas into 
four subclasses, DKK1 (WNT), SFRP1 (SHH), NPR3 (group C) and KCNA1 (group 
D)(7).  However, both NPR-3 and KCNA 1 were subsequently found to be neither 
specific nor sensitive markers and lacked specificity as their expression was identified in 
all subgroups.(7)  
Another study by Min et al (78), molecular subgrouping was based on nuclear expression 
of β-catenin for WNT subgroup, GAB-1 expression for SHH subgroup, NPR3 expression 
in group 3 and KCNA-1 expression in group 4 subroup of medulloblastomas 
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According to Ellison et al (10),  four immunohistochemical markers to aid in molecular 
stratification. Β-catenin was very useful in identifying tumours with WNT signaling 
pathway defects with almost 98% specificity.  Cytoplasmic positivity for GAB-1 was 
seen in internodular areas of desmoplastic variants and therefore useful in identifying 
tumours with defect in SHH pathways. FLI A and YAP-1 negative expression was 
reported to be markers of non-WNT/SHH pathway. The immunohistochemistry profile in 
classifying the molecular subgroups is mentioned in the table below. 
   Table 3 : Immunoprofile of molecular subgroups of medulloblastoma. (79)  
Molecular  
Group 
Immunoreactivity  
GAB1 β - catenin Fillamin A YAP1 
SHH Cytoplasmic Cytoplasmic Cytoplasmic Nuclear  + 
Cytoplasmic 
WNT Negative Nuclear + 
Cytoplasmic 
Cytoplasmic Nuclear  + 
Cytoplasmic 
Non-
SHH/WNT 
Negative Cytoplasmic Negative Negative 
 
MicroRNAs in molecular subclassification of medulloblastomas:(16) 
MicroRNAs (miRNAs) are RNA molecules with 18 to 22 long nucleotide sequences, 
which regulate expression of the protein coding genes.(16) These miRNAs bind to 
multiple target genes at their complementary sequences in the 3′untranslated regions, 
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resulting in gene silencing.  These micro RNAs target several genes and its alteration has 
been reported in several malignancies. Deregulation in micro RNAs plays a vital role in 
pathogenesis of various malignancies.  Micro RNAexpression profile has been found to 
have diagnostic and prognostic potential in the classification of various cancers.(16)  
In a study by Kunder et al(16), MiR-182 was overexpressed in all WNT 
medulloblastomas and in many Group 3 and some Group 4 medulloblastomas, while 
miR-204 was overexpressed in all WNT medulloblastomas and in most Group 4 
medulloblastomas.  MiR-182, miR-135b and miR-204 were found to be under expressed 
in SHH medulloblastomas. MiR-135b was found to be overexpressed in Group 3 and 
Group 4 tumors. MiR-592, a miRNA located within the GRM8 gene, was overexpressed 
in Group 4 medulloblastomas. MiR-10b was expressed at the highest level in WNT 
medulloblastomas, followed by Group 3 medulloblastomas.  MiR-376 expression was 
found to be significantly higher in Group 4 medulloblastomas compared with Group 3 
medulloblastomas. 
Molecular Subgrouping using protein coding gene:(16) 
The 12 protein-coding genes and 11 microRNAs help in classification of four molecular 
subgroups of medulloblastomas. Classification of medulloblastomas into the 4 molecular 
subgroups was demonstrated using a set of 12 protein-coding genes and 9 miRNAs as 
markers by a real-time RT-PCR based assay with an overall accuracy of 97%.  Molecular 
classification  with  the  help  of  9  miRNAs have accuracies of 100%  for  WNT  
subgroup,  93.3%  for  SHH  pathway,  85.7% for group 3 and 100%  for  Group 4. 
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Group 3 and Group 4 tumors have distinct survival rates but with overlapping gene 
expression. MiR-182 and miR-592 was found to be overexpressed in Group 3 tumors and 
group 4 tumours respectively.   MiR-592 and miR-182 are found to be markers for Group 
3/Group 4 classification and also markers for risk stratification of non-WNT,   non-SHH 
medulloblastomas. 
Risk stratification: 
Histology,   molecular features and genetic profiling have refined the stratification of 
disease risk in medulloblastoma.(91)  Various factors that help in disease stratification 
are age, completeness of resection, histological subtypes and genetic markers(92).  
 Modified Chang system is still in use for disease risk stratification(92).  Based on the 
histology, metastasis and genetic profiling, risk stratification can be predicted as low risk, 
standard risk and high risk.(93)  Clinical risk stratification includes only standard risk and 
high risk tumour.   
Current therapy includes surgical resection, craniospinal irradiation and high dose 
chemotherapy based on the risk stratification.(78) Patients with leptomeningeal 
metastasis or incomplete resection are considered to be at high risk.(92) 
Low risk medulloblastomas:  
Nuclear positivity with β-catenin,  absence of metastasis,  large cell 
morphology/anaplastic morphology and MYC amplification are considered to be low 
risk.(94)  
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High risk medulloblastomas: 
Medulloblastomas with metastatic disease,  large cell/anaplastic morphology and MYC 
amplification are high risk group.(94)  
Standard risk medulloblastomas: 
Medulloblastomas which lack discriminating features like metastasis, MYC amplification 
and large /anaplastic morphology were found to have standard risk.(98)  
Cytogenetic abnormalities also play a role in risk stratification. GLI 2 amplification, 14q 
loss and leptomeningeal dissemination identifies the high risk and standard risk patients. 
Presence of GLI 2 amplification alone is identified in patients with poor prognosis. GLI2 
amplification, 14q FISH and metastatic status predicts prognosis for patients having SHH 
medulloblastomas.(13)  Chromosome 8q loss and chromosome 1q gain are the only good 
prognostic markers.(94)  
Treatment: 
Treatments for standard risk patients: 
Patients with standard risk and more than 3 years of age at the time of diagnosis are 
treated with protocols designed to reduce, as far as possible, neuro-cognitive and neuro-
endocrine sequelae, thereby maintaining a low rate of relapse. Progression free survival 
rates for 5 years is 79%-81%.(78) 
Treatment for high risk patients: 
High-risk and non-infant patients are categorized by the presence of metastatic disease 
(M1 / M2 / M3) and /or residual disease.  Five -year progression free survival rates for 
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high risk patients is approximately 60%.(29) The goal in this group of patients is to 
achieve a cure, rather than avoidance of neuro-cognitive and neuro-endocrine sequelae. 
Clinical course: 
Survivors of medulloblastoma will have long term sequelae due to damage from the 
tumour and from radiotherapy treatment. The extent of  impairment is inversely related to 
the age of the patient.(95)  The neuro-endocrine and spinal damage can affect growth, 
bone development and can lead to early puberty. Adverse effects of chemotherapeutic 
regimes include ototoxicity, infertility and can also lead to secondary malignancies.  
Survivors may have lifelong social and educational difficulties resulting in significant 
morbidity.(96)  
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MATERIALS AND METHODS: 
All the procedures carried out in the present retrospective study were approved by the 
Institutional Review Board of Christian Medical College, Vellore. There were a total of 
123 medulloblastomas retrieved from the database of the Department of General 
Pathology, Christian Medical College, Vellore from January 2004 to December 2014.  
Haematoxylin and eosin (H&E) stained and mounted slides and paraffin embedded tissue 
blocks were retrieved from the departmental archives.  
The slides were reviewed for the assessment of the blocks and confirmation of diagnosis. 
One hundred and thirteen medulloblastoma samples had sufficient tissue in the paraffin 
block for performing additional immunohistochemical studies.  Clinical details were 
obtained from the clinical workstation. A detailed review of the H&E stained slides and 
previous immunohistochemical studies was done as detailed in the proforma shown 
overleaf: 
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Title of the study: Histological and molecular subtyping of medulloblastoma  
                              using immunohistochemical markers. 
Biopsy no:                        Name:   
Hospital no:                      Age:                     Gender: 
Histological features: 
A) Pattern:   1) Nodular  2) Lobular 3) Sheets 4) Clusters 5) Streaming 
B) Cellularity:   1) Hypocellular      2) Hypercellular 
C) Size and shape:   1) Small round cells 2) Large cells 
D) Homer Wright rosettes: 1) Present  2) Absent 
E) Cytoplasm:  1) Scant 2) Variable amount of eosinophilic cytoplasm. 
F) Nuclear features: 1. Nuclear pleomorphism     1) Mild      2) Moderate  3)Marked 
                2. Nuclear moulding             1) Present   2) Absent 
                3. Prominent nucleoli            1) Present   2) Absent 
G) Marked cytological atypia       1) Present   2) Absent 
H) Mitotis                                      1) High       2) Low 
I) Apoptosis                                  1) Present   2) Absent 
J) Necrosis                                    1) Present   2) Absent 
K) Differentiation                          1) Neuronal  2) Myogenic  3) Melanotic 4)Glial 
L) Nodular reticulin free zones     1) Present   2) Absent 
M) Histological subtype 
1) Classic 2) Desmoplastic 3) MBEN 4) Large cell variant 5) Anaplastic 
     N) Immunohistochemistry: 
IHC Cytoplasmic Nuclear Cytoplasmic+Nuclear 
Beta 
catenin 
   
GAB-1    
NPR-3    
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Each reviewed case was classified into one of five histological subtypes as follows: 
The tumour was sub classified into each of the variants based on the following features: 
Classic variant: 
Cases with closely packed round to oval cells with hyperchromatic (carrot shaped) nuclei 
surrounded by scant cytoplasm and high mitotic activity were classified as the Classic 
variant. Presence of Homer Wright rosettes was noted.  
Desmoplastic/nodular variant: 
Cases with nodular pattern and reticulin free zones (pale islands) surrounded by densely 
packed cells with a high proliferation rate and dense intercellular reticulum fiber network 
were classified as the Desmoplastic variant. Dense collagenous and reticulin fibres in the 
absence ofa nodular pattern was not considered to be a feature of the Desmoplastic or 
nodular variant. 
Medulloblastoma with extensive nodularity: 
Cases with expanded lobular architecture with enlarged reticulin free zones rich in 
neuropil like tissue were described as medulloblastoma with extensive nodularity. 
Large cell medulloblastoma: 
Cases with a monomorphous population of large cells with large, round, vesicular nuclei, 
prominent nucleoli and variable amount of cytoplasm with abundant mitotic and apoptotic 
figures were categorized as Large cell medulloblastomas. These cells lacked cohesiveness. 
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Anaplastic: 
Cases with the presence of increased nuclear pleomorphism, nuclear moulding, cell-cell 
wrapping and high mitotic activity were described as the Anaplastic variant.  Apoptosis 
was prominent in this variant.  Presence of the above mentioned features in focal areas 
were not considered sufficient to diagnose the Anaplastic variant. 
Myogenic differentiation: 
Cases containing focal rhabdomyoblastic elements, as evidenced by a population of 
spindle shaped cells or large oval cells having abundant eosinophilic cytoplasm that were 
desmin positive, were considered as Medulloblastoma with Myogenic differentiation.   
Slides of previously performed immunohistochemistry were reviewed, which included 
synaptophysin, neuron specific enolase (NSE) and glial fibrillary acidic protein (GFAP). 
On cases suspected to have myogenic differentiation we performed desmin and Myf4 
immunohistochemistry in addition.   
Immunohistochemistry for   β-catenin, GAB-1 and NPR-3 were performed on all 113 
cases using the Ventana Benchmark XT autostainer.  Immunostaining for each antibody 
was standardized to obtain optimal dilutions. The β-catenin antibody was obtained from 
Sigma (purified mouse monoclonal immunoglobulin). Normal human colon was used as 
the positive control and 1:100 was found to be the optimal dilution. (Figure 1) 
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GAB-1 antibody was obtained from Santa Cruz (Rabbit polyclonal antibody) and human 
breast invasive ductal carcinoma, was used as the positive control with 1:50 as the 
optimal dilution. (Figure 2) 
 NPR3 was obtained from Sigma (Rabbit polyclonal antibody).  For NPR3 normal human 
colon was used as the positive control and 1:100 was found to be the optimal dilution. 
(Figure 3) 
The following procedure was followed for performing immunohistochemistry for these 
immunohistochemical markers. 
Protocol for automated immunostaining: 
1. Paraffin embedded tissue sections were cut at 3μ thickness and floated in poly L-
lysine coated slides and incubated overnight at 37˚C. 
2. These slides were then treated with 4% milk solution for 10 minutes to eliminate 
the hydrophobic effect and give a positive charge to the slides. 
3. The slide labels were bar coded and loaded into the fully automated Ventana 
Benchmark XT autostainer. Individual protocols were designed incorporating the 
optimal dilutions for each antibody in the software attached to the machine. The 
steps included in this protocol were as follows:  
a. Deparaffinization 
b. Liquid coverslip application. 
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c. Heat induced antigen retrieval by treating with standard CC1 solution (pH 
patent with the company) for one hour at 90˚C. 
d. Then the primary antibody was added and incubated for 40 minutes at 
37˚C. 
e. The secondary antibody (Multimer) was then added and incubated for 8 
minutes. 
f. Finally the slides were counterstained with Haematoxylin and incubated for 
8 minutes, followed by incubation with the bluing reagent for 4 minutes. 
At the end of each step from antigen retrieval to counterstaining with Haematoxylin, the 
slides were washed with reaction buffer. 
 The sections were dehydrated twice using 80% alcohol to remove the liquid coverslip. 
The slides were dried and the sections mounted in DPX. The antibody clone, dilution, 
source and technique used were as detailed in the table below: 
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Table 4 : Details of  antibody clone, dilution and  source  
 
 
 
 
 
 
 
 
 
 
 
Immunostaining for β-catenin was considered positive if there was uniform intense 
nuclear and/or cytoplasmic staining in more than 10% of tumour cells. Cytoplasmic 
staining in the absence of nuclear staining was considered negative. GAB-1 was 
considered positive if uniform intense cytoplasmic or cytoplasmic membrane labelling 
was seen in more than 10% of the tumour cells.  NPR-3 was considered positive if 
 
ANTIBODY 
  
CLONE 
 
DILUTION 
 
SOURCE 
 
 
β-catenin 
 
 
pThr41 
 
 
1:100 
 
Purified mouse 
monoclonal 
immunoglobulin 
(Sigma) 
 
GAB-1 
 
 
 
H-198 
 
 
1:50 
 
 Rabbit polyclonal      
antibody 
(Santa Cruz) 
 
NPR-3 
 
 
 
PrEST 
 
 
1:100 
Rabbit polyclonal 
antibody 
(Sigma) 
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uniform intense cytoplasmic or cytoplasmic membrane labelling was seen in more than 
10% of tumour cells.  
Statistical Analysis: 
Statistical analysis was done with the Chi square tests using SPSS software. A p value of 
less than 0.05 was considered significant. The patient demographic details and the 
morphological features of each tumor subtype were analyzed.  A chi square test for 
correlation between morphological subtypes and immunohistochemical markers was 
performed.  The specificity and sensitivity of β-catenin among classical and non-classical 
histological subtypes and GAB-1 among the desmoplastic and non-desmoplastic 
histological subtypes were calculated. 
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RESULTS 
There were a total of 123 cases of medulloblastoma from January 2004 to December 
2014. Of these 113 cases were included in the present study based on the defined 
inclusion and exclusion criteria that are outlined in the materials and method section. 
The study population included 26 adults (23%) and 87 children (77%)(Figure 4). The 
mean age at  diagnosis was 13 years(median 11years, range 0-38 years). The mean age 
amongst children was 9 years (median 9 years, range 0-18 years) while in adults it was  
26 years (median 25 years, range 19-38 years).(Figures 5 and 6) 
 
Figure 4:Age distribution among children and adults of medulloblastoma. 
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 Figure 5: Age distribution of medulloblastoma            
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Figure 6:Age distribution of paediatric medulloblastoma 
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The M:F ratio was 2:1 with 66.4% (75 cases) males and 33.6% (38 cases) females 
(Figure 7). In children there was clear male preponderance with nearly two third of the 
cases being males (Figure 8), whilst in adults there was a near equal gender distribution 
(Figure 9). 
 
Figure 7:Gender distribution in medulloblastoma. 
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Figure 8:Gender distribution among children. 
 
 
Figure 9:Gender distribution among adults. 
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Site:  
It was found that 27(23.9%) cases of medulloblastoma arose in the cerebellar hemisphere 
and 86(76.1%) in the midline (Figure 10)  Of those in the midline 21(24.4%) arose from 
the roof of the fourth ventricle, 27(31.4%) from the floor of the fourth ventricle, 
22(25.6%) were seen to arise in the cerebellar vermis and in 16(18.6%) the exact site in 
the midline was not specified as shown in the (Figure 11 ) 
 
Figure 10:Distribution of medulloblastoma by site 
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Figure 11: Distribution by subsite of midline medulloblastoma. 
  
Histological subtypes: 
We found all five histological subtypes of medulloblastoma in our study population. The 
predominant subtype corresponded to the Classic variant at 59.3% (67 cases). 
Desmoplastic medulloblastomas formed the next major group with 22.1 % (25 cases), 
followed by the Large Cell variant at 10.6% (12 cases). There were 6 (5%)  and  3 (2.7%) 
of the Anaplastic and of Medulloblastoma with extensive nodularity (MBEN) subtypes 
respectively. (Figure 12) 
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Figure 12: Distribution of cases by histological subtype in the study population. 
 In adults although Classic variant was the predominant subtype, the Desmoplastic 
variant came a close second constituting 46% and 35% of cases respectively (Figure 13). 
On the other hand in children, the Classic variant constituted nearly two thirds of the 
cases (66%) as opposed to only 19 % being Desmoplastic. (Figure 14).  The age at 
presentation of the three cases of MBEN was 8 years, 10 years and 23 years. The 
proportion of adults and children in each subtype is as shown in Figure 15 . 
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Figure 13: Distribution of cases by histological subtype in adults. 
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Figure 14: Distribution of cases by histological subtype in  children. 
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Figure 15: Distribution by age of the histological subtypes. 
Of the 27 medulloblastomas seen in the cerebellar hemispheres, the majority, 59.3% were 
of the Desmoplastic variant (16 cases) and a quarter of the cases were of the Classic 
variant, 07/27 (25.9%) (p<0.001).The proportion of the other histological variants seen in 
the cerebellar hemispheres was as shown in Figure 16.  Of 86 medulloblastoma in the 
midline 60 (69.8%) were of Classic histology (p<0.001) (Figure 17) .  
 
58 
 
 
Figure 16:Distribution by histological subtype in the cerebellar hemisphere. 
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Figure 17: Distribution by histological subtype in the midline. 
 
Amongst the Desmoplastic tumours, 57.1% occurred in the cerebellar hemisphere as 
shown in the Figure 18. 
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Figure 18: Distribution by histological subtype in the cerebellar hemisphere 
 
Histological Features: 
The Classic subtype was characterized by closely packed round to oval cells with hyper-
chromatic (carrot shaped) nuclei surrounded by scant cytoplasm and high mitotic 
activity.(Figures 19(a)-19(i)) 
The Desmoplastic variant was characterized nodular pattern and reticulin free zones (pale 
islands) which were surrounded by densely packed cells  with  dense intercellular 
reticulin.(Figure 20a-20c.) Those cases with only dense collagenous and reticulin fibres 
without any nodular pattern were not classified as Desmoplastic or nodular 
variant.(Figure 20(d)&20(e)) 
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The MBEN variant was characterized by expanded lobular architecture with enlarged   
reticulin free zones rich in neuropil like tissue.The tumour cells had uniform nuclei and 
clear cytoplasm resembling neurocytes.(Figure 21(a)-21(f)). 
The Large Cell variant was characterized by monomorphous population of cells with 
large, round, vesicular nuclei, prominent nucleoli and variable amount of cytoplasm with 
abundant mitotic and apoptotic figures.(Figure 22(a)-22(c)) 
The Anaplastic variant was characterized by the presence of increased nuclear 
pleomorphism, nuclear moulding, cell-cell wrapping and high mitotic activity.  Apoptosis 
was prominent in this variant.  Presence of the above mentioned features in focal areas 
was not considered sufficient to diagnose an anaplastic variant.(Figure 23(a)&23(b)) 
There was one case with myogenic differentiation which was seen  in a case of 
medulloblastoma, Classic variant. There were no cases with melanocytic differentiation. 
(Figure 24(a)-24(d)) 
Rosettes: 
In the present study, rosettes were seen in 37 cases out of the total 113 cases (33.7%). 
(Figure 25(a&b)). Although rosettes were not restricted to any one subtype, nearly two 
thirds of the cases with rosettes were of Classic histology, and about 10% were of the 
Anaplastic variant.(Figure 26) 
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Figure 26: Prevalence  of rosettes in the histological subtypes. 
Nuclear moulding: 
Nuclear moulding was present in 12 out of the 113 cases (10.6 %), with 05/12 cases 
(41.6%) being of the  anaplastic variant.(Figure 27)  
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Cell to cell wrapping: 
Of the total 113 cases of medulloblastoma, 10 cases (8.8 %) showed cell to cell wrapping 
with  05/10 cases(50%) being seen in the anaplastic variant.(Figure 28) 
β-catenin immunoexpression: 
β-catenin showed nuclear positivity in 23 cases(Figure 29(a)&29(b)) and both nuclear 
and cytoplasmic positivity in 27 cases.(Figure 29(c))  Cytoplasmic positivity in the 
absence of nuclear staining was seen in 7 cases and in 56 cases there was no 
immunostaining. (Figure 29(d)). Thus 44.2% (50) cases were immunopositive   and 
55.8% (63) cases were immunonegative  for β-catenin.  
Demographic profile and β-catenin immunoexpression: 
β-catenin immunoexpression was seen in 78% children versus 22% of adults, 
 this difference  was statistically significant. (p <0.001) (Figure 30) 
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Figure 30(a): β-catenin immunoexpression among children and adults. 
 
 
 
Figure 30(b) :Distribution by age in years of β-catenin immunoexpression  
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β-catenin  immunoexpression was seen in 68% males versus 32% female, this difference  
was  statistically significant.  (p = 0.0007) (Figure 31)  
 
Figure 31.: β-catenin immunoexpression among males and females. 
 
β-catenin immunoexpression and site : 
Of the 27 tumours  seen in the cerebellar hemispheres  22(81.5%) were negative for β-
catenin. Of the tumours in the midline a little over 50% were positive for β-
catenin.(Figure 32).  
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Figure 32:Distribution by β-catenin immunoexpression in the different sites. 
 
On further analysis amongst the midline tumours, of those that arose from either the roof 
of the fourth ventricle or cerebellar vermis,  21 (48.8%) tumours were positive for β-
catenin  and  22 (51.2%) tumours were negative for β-catenin.  Of those that arose in the 
floor of the fourth ventricle 18 (66.7%) were positive for β-catenin  and 9 (33.3%) were 
negative for β-catenin (Figure 33 ). This difference was not found to be statistically 
significant (p value 0.22).  
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Figure 33: Distribution by β-catenin  immunoexpression in the midline 
medulloblastomas. 
 
β-catenin immunoexpression and histological subtypes: 
The Classic variant variant constituted 88% of the β-catenin positive cases (Figure 34 ).  
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Figure 34: Prevalence of  β-catenin positivity in the histological subtypes. 
Among the five histological patterns β-catenin immunoexpression was seen  in  the 
majority of cases with  Classic histology 65.7% (44 out of 67 cases)  followed by Large 
Cell (4/12 cases) and Anaplastic variants (2/6 cases viz., 33.3% each). None of the 
Desmoplastic variant or Medulloblastoma with extensive nodularity were β-catenin 
positive. (Figure 35) 
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Figure 35: Distribution by β-catenin immunoexpression among the histological subtypes. 
GAB-1 immunohistochemistry: 
GAB-1 immunoexpression was seen in 23% (26) of  cases(Figures 36(a)-36(c)).  
Demographic profile and GAB-1 immunoexpression: 
GAB-1  immunoexpression was seen in 61.5 % children versus 38.5% of adults, 
this difference was not statistically significant. (p = 0.16)(Figure 37(a&b) 
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Figure 37(a): GAB-1 immunoexpression among children and adults. 
 
 
Figure 37(b): Distribution by age in years of GAB-1 immunoexpression  
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GAB1   immunoexpression was seen in 57.7% males versus 42.3% female, a 
difference that was not statistically significant. (p = 0.40)(Figure 38) 
 
Figure 38:GAB-1 immunoexpression among males and females. 
GAB-1 immunoexpression and site: 
Of the 27 tumours that occurred in the cerebellar hemispheres 16 (59.1%) were 
immunopositive for GAB-1 (Figure 39). Of those tumours that occurred in the midline 76 
88.4% (76 cases) were immunonegative for GAB-1.  This difference was found to be 
statistically significant (p=0.002).  
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Figure 39:Distribution by GAB-1 immunoexpression in the different sites.  
On further analysis amongst the midline tumours, of those that arose from either the roof 
of the fourth ventricle or cerebellar vermis only 04 (9.3%) were GAB-1 positive and 
amongst those that are from the floor of the fourth ventricle only 2(7.4%) were GAB-1 
positive(Figure  40) sites. 
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Figure 40: Distribution by GAB-1 immunoexpression in midline medulloblastoma. 
GAB-1 immunoexpression and histological subtype 
Nearly three fourth of the cases were of the Desmoplastic variant (19cases). (Figure 41)  
Amongst the Desmoplastic medulloblastomas, 76% (19/25) cases showed GAB-1 
immunopositivity. (Figure 42)  
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Figure 41: Prevalence of GAB-1 immunoexpression in the histological subtypes.  
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Figure 42 : Distribution by GAB-1 immunoexpression among the histological subtype. 
Correlation between β-catenin and GAB-1: 
The majority of GAB-1 positive cases were β-catenin negative (24/26). Of the two GAB-
1 positive cases that were also β-catenin positive , 1  was of Desmoplastic histology and 
showed nuclear immunopositivity  and the other was of  Classic histology and  showed 
both nuclear and cytoplasmic  immunopositivity for β-catenin. There were 39 cases that 
were negative for both  β-catenin and GAB-1.  
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Table 5: Comparison of β-catenin and GAB-1 immunoexpression  
 β-catenin Total 
GAB-1 POSITIVE NEGATIVE  
CYTOPLASMIC NUCLEAR NUCLEAR 
     + 
CYTOPLASMIC 
  
Positive 1 1  1 23 26 
Negative 6 22 26 33 87 
Total 7 23 27 56 113 
 
NPR-3: 
In the study population, only 2 cases (1.8%) showed NPR-3 positivity. Of the NPR-3 
positive cases one was a Classic variant medulloblastoma and the other was a large cell 
variant of medulloblastoma.(Figure 43) 
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DISCUSSION 
Medulloblastomas are  high grade embryonal tumours  of the central nervous system 
accounting for nearly 20% of  childhood brain tumors and less than 1% of  adult CNS 
tumors.(96)   Although high grade, current management strategies have resulted in better 
long-term survival. (97)   The 2007 WHO classification defines five histological subtypes 
of medulloblastoma, namely the Classic, Desmoplastic/nodular, Medulloblastoma with 
extensive nodularity, Anaplastic and Large Cell variants. (3)  The developing cerebellum 
undergoes differentiation aided by  signaling pathways such as Shh , Notch and WNT 
pathways .(63)  A key mechanism involved,  in  tumorigenesis is believed to be 
dysregulation of  some of these signaling pathways.(27)  The wingless (WNT) and sonic 
hedgehog (Shh) signaling  pathways are prime amongst those incriminated and several 
studies have identified  the involvement of these two pathways in different subsets of 
medulloblastomas reliably and consistently. (98)  
The present study was carried out with the aim of classifying adult and paediatric 
medulloblastomas, seen in this institution over a ten year period, into the histological 
subtypes as defined by WHO and to correlate the expression of markers of the WNT and 
SHH signaling pathways namely,  β-catenin, GAB-1 and NPR-3, with these histological 
subtypes. 
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Medulloblastomas are 10 times more common in children when compared to adults. (99)  
In the present study more than three fourths of the medulloblastomas were seen in 
children. The mean age at diagnosis of the overall cohort in the present  study  was 13 
years. The mean age was however lower at 9 years when considering only the paediatric 
medulloblastomas. The majority of the paediatric medulloblastomas  in this study were 
seen between the ages of 5 and 14 years with the peak incidence being in the 8-11 years 
age group . Whilst other studies have reported a bimodal age distribution with peaks 
between 3-4 years and 8-9 years, we found a gradual increase in incidence from 2 years 
of age,  peaking at 9 years and then gradually declining in incidence by age 18 years. 
(100)  In present study, the mean age at diagnosis in adults was 26 years. This is contrast 
to the  study by Giordana et al  which reported a  peak incidence in the age group of 15-
19 years.(101)  It is pertinent to note that the cut –off for pediatric age in the current 
study was 18 years and this might explain the difference in peak age at diagnosis in adults 
between our study and that of Giordana et al.(101)  The reported incidence of adult 
medulloblastoma is upto 30%. In our study 23% of medulloblastomas were seen in 
adults.(100)  
In the present study, a male preponderance was noted with twice as many males as 
females in the overall cohort.  Amongst children,  nearly  two third of medulloblastomas 
were seen in  males which is in keeping with the published literature (8).   In contrast 
there was an almost equal gender distribution in adults.  Giordana et al reported a male 
preponderance in adults.(101)  
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Medulloblastomas occur at two sites, the cerebellar hemispheres and in the midline from 
the cerebellar vermis projecting into the fourth ventricle and impinging on brain stem. (3)  
Most medulloblastomas arise in the midline. The tumors that are laterally situated are 
seen in older children, adolescents and adults. (77) In the present study over three fourths 
of the cases were seen in the midline.   
Histological subtypes: 
All the five histological subtypes as defined by the WHO were noted in this study.  
Among the five histological subtypes the Classic variant  was found to be the 
predominant subtype constituting about 59.3%(67 cases) followed by the Desmoplastic 
variant 22.1% (25 cases) and the Large Cell variant at 10.6% (12 cases) . The prevalence 
of the different subtypes is similar to that reported by others .(102) 
In adults, nearly a third of the cases were of  the  Desmoplastic variant in contrast to 
children, where the Desmoplastic variant constituted only 1/5
th
 of the cases. The 
Desmoplastic variant has a higher prevalence in infants and adults. (77)  There were no 
infants with Desmoplastic medulloblastoma in our study. Moreover, amongst the 16 
cases of  Desmoplastic medulloblastoma seen in the paediatric age group, the range was 
from 3-17 years with  the mean age at diagnosis being 9.9 years. 
Medulloblastoma with extensive nodularity, usually presents at the age of 3years or 
younger . (103)  However, in the present  study,  of the 3 cases of MBEN, 2 were seen in 
children and one in an adult. The two children were aged 8 and 10 years.  In a study by 
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Garre et al(104) on age – dependant occurrence of medulloblastoma, 2 of the 12 cases 
were seen at 4 years and 6 years. However, the remaining 10 were less than 3 years of 
age.  Our finding that the MBEN variant is not restricted to adults is unusual and larger 
cohorts from the Indian subcontinent should be studied to determine if this is due to 
genetic variations.   
Rosettes: 
Homer Wright rosettes are described as a feature of medulloblastoma. Although not 
universally seen, at least 40% of medulloblastomas are reported to contain Homer Wright 
rosettes,  particularly in the Classic variant. (68)  In the  present study Homer Wright 
rosettes were seen in 33.7% (37 cases). About two thirds of these cases were of the  
Classic variant and about 10.8% of the cases were of Anaplastic histology. 
Wingless Pathway Tumors 
The WNT/ β-catenin  signaling pathway plays a role in regulating embryogenesis of the 
brain.   WNT/ β-catenin  signaling  pathway activation when unregulated leads to 
upregulation of transcription and  imbalance in cell proliferation  resulting in  tumor 
formation .  (27)  
Nuclear expression of β-catenin  with activation of WNT signaling pathways are seen in 
10% of the sporadic medulloblastomas.(100)  In present study,  44.2% of cases showed  
immunopositivity β-catenin . This is much higher than that reported by several (73) (100) 
who found  positivity for β-catenin in 5-15% of medulloblastomas.  In a study by Ellison 
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et al published in 2005 on 109 medulloblastomas, nuclear positivity for  β-catenin  was 
found in 25% of cases. (72)  . A similar prevalence was reported by Clifford et al. 
However, a more recent study by the Ellison et al on a larger series, reported a more 
modest prevalence of WNT subgroup at 14%. .   In studies from India by Kaur et al (105) 
, activation of the WNT signaling pathway was seen in 9.8% and 5.2% of cases 
respectively.  
WNT pathway activated  tumours  are of classic histology,  occurs in non infants and 
have dual peak of  incidence at 10 and 20 years.(26) They are equally distributed between 
both genders. (100)  In the present study a peak incidence was seen at 7 years of age and 
68% of those with activation of  WNT pathway were males.  
In present study , among  the five histological patterns,  β-catenin  immunoexpression 
was  seen  in a majority of the cases with  Classic  histology 65.7% (44 out of 67 cases).  
None of the Desmoplastic variant or medulloblastoma with extensive nodularity were β-
catenin positive.  Subsets of both Classic and Large Cell variants have been found to have 
activation of the WNT signaling pathway.(100)  In the current study 4 of 12 Large Cell 
variants and 2 of 6 and Anaplastic variants showed nuclear positivity for β-catenin.  
Sonic Hedgehog Pathway Tumors: 
Sonic hedgehog (Shh) is a ligand that is secreted by the Purkinje cells of the developing 
cerebellum and promotes the replication of cells in the external granular layer. Shh binds 
to PTCH receptors which normally function as inhibitors of the transmembrane protein 
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Smoothened (SMO). This results in derepression of SMO, which in turn results in 
activation of Gli transcription factors. Suppressor of Fused (SUFU) also inhibits Shh 
signaling. Mutational inactivation of PTCH, mutation of SUFU, activating mutations of 
SMO  all lead to activation of the Shh/PTCH pathway. (106) Shh pathway activation has 
been reported in over 25% of medulloblastomas. (107) The Desmoplastic/nodular variant 
has a close association with PTCH mutations (108) and mutations of SMO and SUFU.  
In the present study, GAB-1 immunoexpression was seen in 23% (26) of cases. The Shh 
sub group of tumors  are seen in about 30% of medulloblastomas overall. (100)  The Shh 
subgroup has a bimodal distribution, seen more commonly in children younger than 3 
years and in patients older than 16 years.  They have an equal gender distribution(100). In 
our study, 61% of GAB-1 positive cases were seen in children, however there was no 
increase in any particular age group of children. There was a slight male preponderance. 
Nearly three fourths of the cases with GAB-1 expression were of the desmoplastic 
variant. This data is keeping with previous studies.(72) Amongst the desmoplastic 
medulloblastomas,  76%  (19/25) cases showed GAB-1 immunopositivity compared to 
the study by Ellison et al ((72))  in which  54% of desmoplastic tumours were of the  Shh  
subgroup .   
In present study, most of the GAB-1 cases were β-catenin negative (24/26).  A study by 
Min et al(7) showed 3 cases with both nuclear β-catenin  and GAB-1 expression, but one 
these cases showed monosomy 6 which was helpful in including the case under WNT 
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subgroup. This overlap of expression of β-catenin  and GAB-1 may represent the 
concurrent activation of both Shh and WNT pathways in the development of 
medulloblastomas. 
A study by GIBSON et al (27) found that WNT subgroup and Shh subgroup are 
anatomically distinct.  Medulloblastoma with WNT signaling pathway activation  are 
found to be infiltrate the dorsal brainstem  and those with Shh pathway activation are 
located in the cerebellar hemispheres.  Recent work in mouse models has also reported 
the expression of WNT pathway target genes in the lower rhombic lip of the cerebellum 
at day 11.5 of embryonic development,  and the dorsal brainstem at day 15.5.  In the 
present study 59% of tumors that were localized to the cerebellar hemispheres  were 
found to be immunopositive for GAB-1, indicative of Shh pathway activation.  
We also found that  of the 27 cases seen  in relation to the floor of the fourth ventricle, 18 
(66.6%) were positive for β-catenin  , which is in keeping with the finding that 
developmentally, the lower rhombic lip of cerebellum and dorsal brain stem express 
WNT pathway genes.  
Non-WNT/Shh Tumors 
Group 3 and Group 4 tumors are considered in the non-WNT/SHh subgroup. (7) Genetic 
driver mutations in these are yet to be established. There were 39 cases belonging to the 
nonWNT/Shh subgroup in our study, comprising 34.5% of cases. Kaur et al(105) 
reported a prevalence of 44.6% of this sub group.  
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Group 3 medulloblastomas are common in children, have the least favorable outcomes  
and have an increased incidence of leptomeningeal dissemination. They   account for 
25% of all medulloblastomas(107) . This group is characterized by large cell/anaplastic 
histology, chromosome 7 gain, chromosome 8 loss and NPR-3 expression.  Min et al 
found that NPR-3 lacked sensitivity in the diagnosis of Group 3 tumors as it showed 
positivity in only 2 cases  and one of these cases belonged to the WNT subgroup with 
CTNNB1 mutation.(7) 
In present study, only 2 cases(1.8%) showed NPR-3 positivity.  One was a  Classic 
variant  and the other a Large Cell variant of medulloblastoma.  
Molecular sub grouping has allowed for categorization of  medulloblastomas in ways that 
have prognostic and therapeutic significance.  The  present study represents the first step 
in characterization of the cohort of cases seen in our institution. Apart from expanding 
the panel of markers to completely characterize this cohort, future studies will require 
incorporation of more detailed genomic platforms to segregate these tumors in 
appropriate subtypes.  Studies aimed at correlating   treatment protocols and outcome 
with these histological and molecular subtypes are warranted to optimize  treatment 
protocols and for prognostication. While we utilized antibodies to GAB-1 and β-catenin  
to identify the two major subtypes of medulloblastomas, namely Shh and WNT,  a larger 
panel of antibodies is required to better characterize this heterogeneous group of tumors. 
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Although histological subtyping  of medulloblastomas has not been entirely supplanted, it 
is quite clear that histology alone is irrelevant in isolation and that identification of 
molecular sub groups is of paramount importance clinically. The challenge we face in the 
Indian setting, is to develop simple inexpensive techniques  for sub- typing that can  be 
adopted universally.  Inter-center cooperation and setting up of core facilities for testing 
may be the way forward. 
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CONCLUSIONS 
 
 Medulloblastomas are primarily tumors of childhood and 77% of the study population 
were children. 
 The mean age at  diagnosis of medulloblastomas was 13 years.  
 The mean age amongst children was 9 years ,while in adults it was  26 years  
 The M:F ratio of medulloblastomas was 2:1. In children there was clear male 
preponderance, whilst in adults there was a near equal gender distribution 
 Medulloblastomas occurred predominantly in the midline with only a quarter arising 
laterally in the cerebellar hemisphere.  
 The predominant histological subtype corresponded to the Classic variant. 
 Desmoplastic medulloblastomas formed the next major histological variant,  followed by 
the Large Cell variant  
 Anaplastic and of Medulloblastoma with extensive nodularity (MBEN) subtypes formed 
<5% of medulloblastomas 
 In adults, the Classic variant and the Desmoplastic variant had a nearly equal prevalence. 
 In children, the Classic variant constituted nearly two thirds of the cases 
 Medulloblastomas in the cerbellar hemispheres were predominantly of the Desmoplastic 
variant.  
 Midline medulloblastomas were predominantly of the Classic variant. 
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 WNT signaling activation as evidenced by β-catenin immunoexpression was seen in 
44.2% of medulloblastomas. 
 WNT signaling activation was seen predominantly in males and children. 
 Over 50% of midline medulloblastomas showed WNT signaling activation  
 WNT signaling activation was seen  in  the majority of cases with  Classic histology 
65.7%, followed by Large Cell and Anaplastic variants  
 None of the Desmoplastic variant or Medulloblastoma with extensive nodularity showed 
activation of  the WNT signaling pathway. 
  Shh signaling activation as evidenced by GAB-1 immunoexpression was seen in 23% of 
medulloblastomas. 
 Shh signaling activation was seen predominantly in children, with a near equal gender 
distribution. 
 Nearly 60% of  medulloblastomas arising laterally in the cerebellar hemisphere  showed 
Shh signaling activation  
 Nearly three fourth of the cases with Shh signaling activation were of the Desmoplastic 
variant  
 The non WNT/Shh sub-group constituted 34.5% of medulloblastomas. 
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LIMITATIONS 
 
 Complete molecular sub-typing was not feasible as the battery of 
immunohistochemical markers was limited to three, owing to financial constraints.  
 Treatment and Follow-up data was not obtained in the present study. This is 
required to ascertain true prognostic relevance of sub-typing.  
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               Figure 1(a)&(b):  β- catenin: Nuclear positivity  in control colonic epithelium. 
              A)Low power magnification(x100), B)High power magnification(x400) 
 
  
            Figure 2(a)& (b): GAB-1: Showing cytoplasmic positivity in control invasive ductal 
            carcinoma, breast A)Low power magnification (x100),  B)High power 
            magnification (x400) 
 
  
            Figure 3(a)&3(b): NPR-3: Cytoplasmic positivity in control normal colon. A) Low       
            Magnification (x100), B) High power magnification (x400) 
 
             Figure 19(a):Classic variant of medulloblastoma with closely packed cells 
            (H&E, x100) 
 
          Figure 19(b): Classic variant of medulloblastoma with medium sized hyperchromatic 
            nuclei and scant cytoplasm (H&E, x400) 
             Figure 19(c): Carrot shaped nuclei in classic medulloblastoma (H&E, x400) 
 
 
            Figure 19(d):Numerous mitotic figures in classic variant of medulloblastoma 
            (H&E, x400) 
  
 
 
 
 
 
 
 
      Figure 19(e):Synaptophysin positivity in classic variant of medulloblastoma (x400) 
 
 
 
 
 
 
 
 Figure 19(f): Classic medulloblastoma with leptomeningeal invasion (H&E,  x40) 
 
 
       Figure 19(g): Classic medulloblastoma with leptomeningeal invasion  (H&E, x100) 
           Figure 19(h): Classic medulloblastoma with leptomeningeal invasion  (H&E,  x200) 
 
 
            Figure 19(i): Stromal desmoplasia associated with leptomeningeal invasion 
           (Retic,x200) 
             Figure 20(a):Desmoplastic/nodular medulloblastoma highlighting the pale 
            nodules(H&E,x100) 
 
            Figure 20(b): Nodular reticulin free zones in a desmoplastic medulloblastoma  
              (Retic,x100) 
  
 
           Figure 20(c): Neuronal differentiation in the nodules evidenced by immunopositivity 
             for   synaptophysin. A)Low power magnification(x40)  B)High power 
             magnification(x200) 
           Figure 20(d):Streaming in a classic  medulloblastoma with absent nodularity (H&E, 
            x100) 
 
    Figure 20(e):  Associated stromal desmoplasia. Note the absence of reticulin free 
            nodules. (Retic, x100) 
             Figure 21(a) :Medulloblastoma with extensive nodularity (H&E, x40) 
 
 
            Figure 21(b): Medulloblastoma with extensive nodularity (H&E, x100) 
          Figure 21(c): Medulloblastoma with extensive nodularity with large reticulin free 
             zones(Retic, x100) 
 
 
            Figure  21(d): Medulloblastoma with extensive nodularity with  neurocytic 
           differentiation(H&E, x200) 
             Figure  21(e): Medulloblastoma with extensive nodularity  with neurocytic 
            differentiation (H&E, x400) 
 
            Figure  21(f): Medulloblastoma with extensive nodularity  with small round 
            neurocytic cells in a fibrillary background(H&E, x400) 
             Figure 22(a): Large cell medulloblastoma large vesicular nuclei with prominent 
           nucleoli (H&E,x400) 
 
 
            Figure 22(b):Numerous apoptotic bodies in a large cell medulloblastoma(H&E, x400) 
  
 
 
 
 
           Figure 22(c):Synaptophysin displaying dot like positivity in a large cell  
          medulloblastoma(x400) 
 Figure 23(a):Anaplastic medulloblastoma with increased nuclear pleomorphism 
             and high mitotic activity(H&E,x400) 
         
 
Figure 23(b): Brisk mitotic activity in an anaplastic medulloblastoma(H&E, x400) 
  
           Figure 24(a&b): Medulloblastoma with myogenic differentiation . Note the 
          component of classic  varaint in thelower left quadrant. A)Low power magnification  
           (H&E,x100)  B)High  power magnification (H&E,x200) 
           Figure 24(c) :Medulloblastoma with myogenic differentiation highlighting the strap 
cell (H&E, x200)            
 
            Figure 24(d): Rhabdomyoblasts in the Medulloblastoma with myogenic  
           differentiation (H&E,x400) 
  
 
            Figure 24(d):Desmin immunostaining of  the myogenic component in 
            medulloblastoma  with myogenic differentiation.A)Low power magnification (x100) 
           B)High power magnification(x400). 
  
            Figure 25(a&b): Classic Medulloblastoma with numerous Homer Wright rosettes 
           A)Low power magnification(H&E, x100) , B)High power magnification(H&E,x400) 
 
 
 Figure 27: Nuclear moulding in an anaplastic medulloblastoma (H&E,x400) 
 
 
Figure 28: Cell to cell wrapping in an anaplastic medulloblastoma (H&E, x400) 
 
             Figure  29(a):β catenin nuclear immunoreactivity in a classic variant of 
            medulloblastoma(x400) 
 
       Figure 29(b):Both nuclear and cytoplasmic β catenin positivty in a classic variant of 
medulloblastoma (x400) 
            Figure 29(c) :β- catenin immunopositivity in the medulloblastoma with 
leptomeningeal invasion(x100) 
 
 
      Figure 29(d): Medulloblastoma immunonegative for β-catenin (x400) 
             Figure 36 (a)..:GAB-1 immunopositivity in internodular areas of a desmoplastic 
            medulloblastoma (x100) 
 
            Figure 36(b):Cytoplasmic membrane positivity of GAB-1 in a desmoplastic 
            medulloblastoma(x400) 
  
 
 
 
 
 
 
 
                   Figure 36(c):GAB-1 immunonegativity in a classic medulloblastoma(x400) 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
     Figure 43: Medulloblastoma with  immunoreactivity for NPR-3 (X400) 
